This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Released: July 12, 2026·Last reviewed: August 4, 2026·Methodology v4.1

Researched By

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: August 4, 2026 · This page is informational and does not constitute medical advice.

This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

GLP-1 medications and menopause

Quick answer

Menopause is associated with metabolic shifts and weight gain, and GLP-1 medications are increasingly used in this population. They are not menopause treatments; they address weight and glycemic control, and eligibility and safety are individual clinical questions.

Why interest is rising

Hormonal changes around menopause can shift fat distribution and make weight harder to manage. GLP-1 agents target appetite and metabolism, which is why interest has grown — but they treat weight, not menopause itself.

What to consider

Bone and muscle health matter more with age; muscle-preserving strategies (protein, resistance training) pair with GLP-1 therapy. Discuss individual risks with a clinician.

Frequently asked questions

Can GLP-1 medications help with menopause weight gain?

They can support weight management in this population, but they are not menopause therapies and eligibility is an individual clinical decision.

Sources

U.S. Food and Drug Administration — labels and safety communications.
Peer-reviewed clinical trials cited above.
Our methodology and medical review policy.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.